<DOC>
	<DOCNO>NCT00624325</DOCNO>
	<brief_summary>For chronic hepatitis C patient unresponsive previous ( PEG- ) IFN/RBV combination therapy propose continuous subcutaneous administration high-dose IFN-a2b ( Intron A® ) 48 week combination 15 mg/kg/day RBV ( Rebetol® ) optimal management side effect order maintain high possible dosage IFN-a2b RBV 48 week . We expect improve tolerability continuous subcutaneous pump delivery IFN-a2b compare thrice weekly daily subcutaneous injection IFN-a2b , increase antiviral activity biologic potency due sustain high level fully potent interferon protein .</brief_summary>
	<brief_title>Subcutaneous Continuous Infusion Interferon Alfa-2b Ribavirin Hepatitis C Genotype 1 Nonresponders</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Hepatitis C genotype 1 unresponsive ( peg ) interferon /ribavirin therapy In past , peginterferon conventional interferon plus ribavirin combination therapy least 12 week less 2log HCV RNA decrease week 12 , HCV RNA positivity week 24 , breakthrough therapy relapse therapy At least 12 week end ( peg ) interferon/ribavirin therapy start highdose IFN/ribavirin therapy Persistent indication antiviral therapy persistently elevate serum ALT histological evidence continue progressive fibrosis Age 1860 year Signs progressive liver disease since end previous therapy , beyond generally accept criterion HCV antiviral therapy : serum bilirubin &gt; 35 μmol/l , albumin &lt; 36 g/l , prothrombin time &gt; 4 sec prolong platelet &lt; 100,000/mm3 decompensated cirrhosis ( defined jaundice presence cirrhosis , ascites , gastric bleeding , esophageal varix encephalopathy ) Hepatic imaging ( US , CT MRI ) evidence hepatocellular carcinoma ( hepatic imaging perform within 3 month prior screen ) alpha fetoprotein &gt; 50 ng/ml Other acquire inherited cause liver disease could explain liver disease activity Coinfection hepatitis B virus human immunodeficiency virus ( HIV ) Other significant medical illness might interfere study : significant cardiovascular , pulmonary renal dysfunction , malignancy skin basocellular carcinoma previous 5 year , immunodeficiency syndrome ( e.g . : HIV positivity , steroid therapy , organ transplant cornea hair transplant ) History severe seizure disorder current anticonvulsant use History thyroid disease poorly control prescribed medication Contraindications IFN and/or ribavirin : Severe psychiatric disorder , major psychosis , suicidal ideation , suicidal attempt and/or manifest depression previous ( peg ) interferon therapy . Severe depression would include follow : ( ) subject hospitalized depression , ( b ) subject receive electroconvulsive therapy depression , ( c ) subject whose depression result prolonged absence work and/or significant disruption daily function . Subjects history mild depression may consider entry protocol provide pretreatment assessment subject 's mental status support subject clinically stable ongoing evaluation patient 's mental status study Reactivation immunological disorder previous therapy Visual symptom related retinal abnormality Pregnancy , breastfeed inadequate contraception Thalassemia , spherocytosis Substance abuse , alcohol ( ³80 gm/day ) I.V . drug . If subject history substance abuse , consider inclusion protocol , subject must abstain use abused substance least 2 year Any condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>genotype 1 nonresponders</keyword>
</DOC>